Saturday 17 October 2026
Export RGNT’s income statement to Excel — free account
Regentis Biomaterials Ltd.
RGNT Healthcare Medical Instruments & Supplies
1.49
0.06
−3.87%
Follow RGNT
| Dec '25 | Dec '24 | Dec '23 | |
|---|---|---|---|
Current Ratio |
2.65 | 0.07 | 0.11 |
Net Debt/EBITDA |
0.89 | 5.06 | (3.76) |
Debt/Assets |
15.71% | 1,025.93% | 2,115.28% |
Debt/Equity |
0.25 | (0.12) | (0.17) |
Asset Turnover |
0.00 | 0.00 | — |
Operating CF/Net income |
0.10 | (0.13) | 0.29 |
| 75.31% | (10.93%) | 0.00% | |
| (338.07%) | 1,128.98% | 0.00% | |
ROIC |
0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(288.62%) | (79.14%) | 150.41% |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | — | — |
Free Cash Flow per Share |
(2.43) | (0.23) | (7.03) |
Cash per Share |
13.02 | 0.08 | 1.99 |
Shareholders Equity per Share |
8.37 | (14.86) | (264.58) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 |
Book value per Share |
8.37 | (14.86) | (264.58) |
Free Cash Flow |
(1.37) | (0.64) | (1.22) |
Working Capital |
4.74 | (6.01) | (2.78) |
Net Current Asset Value |
4.74 | (41.10) | (45.90) |
| Other line items | |||
Quick Ratio |
2.57 | 0.04 | 0.11 |
Cash ROIC |
(10.32%) | 1.78% | 3.22% |
Accounts Payable Turnover |
0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 | 0.00 |
Operating CF per Share |
(2.43) | (0.23) | (7.03) |
Capex per Share |
0.00 | 0.00 | 0.00 |
Average Payables |
0.26 | 0.30 | — |
Average Assets |
4.05 | 0.42 | — |
Average Common Equity |
(18.18) | (43.50) | — |
Columns are period end dates